[Comment] Beyond efficacy: CDK4/6 inhibitors in metastatic breast cancer
Summary
Over the past decade, phase 3 trials have consistently demonstrated substantial progression-free survival and overall survival improvements with the addition of CDK4/6 inhibitors to endocrine therapy. The meta-analysis of Beshr and colleagues1 in The Lancet Oncology provides the most up-to-date analysis of data from phase 3 trials comparing CDK4/6 inhibitors plus endocrine therapy with endocrine therapy alone. By co…
Over the past decade, phase 3 trials have consistently demonstrated substantial progression-free survival and overall survival improvements with the addition of CDK4/6 inhibitors to endocrine therapy. The meta-analysis of Beshr and colleagues1 in The Lancet Oncology provides the most up-to-date analysis of data from phase 3 trials comparing CDK4/6 inhibitors plus endocrine therapy with endocrine therapy alone. By consolidating survival results, efficacy of this drug class in treatment of HR+/HER2– metastatic breast cancer is reaffirmed.